Apply for the Job in Executive Director, US Marketing, Multiple Myeloma at Santa Monica, CA. Use our tool to get a personalized report on your market worth. As we kick off #BlackHistoryMonth, Belinda Moore shares her experience balancing her Patient Support Strategy role while also helping to lead the Gilead Leadership Organization of Black Employees resource group. Expert-level of knowledge of the biopharma industry, including in-depth understanding of other business functions, as evidenced by proven track record of leading organizations and teams to achieve short- and long-range strategies, plans, and objectives. Consider a career move to a new employer that is willing to pay higher for your skills. The organizational functions at Gilead Sciences that pay the least are administrative and accounting. Executive Director COVID and Emerging Viruses - linkedin.com The estimated additional pay is $229,203 per year. A shift towards, Handling involuntary termination is a likely occurrence for human resources managers and, Return better results with Payscale job search, Compare real living costs across different states, Consider potential directions your career can take, Calculate the 20-year net ROI for US-based colleges, Are you the kind of person who struggles to get a handle, Learn where the best career earners attended college, The average salary for an Executive Director is $278,109. Learn about the talented people at Gilead who are working to solve some of the worlds biggest healthcare challenges. Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Gilead Sciences Executive Director Salaries | Glassdoor Employees working in the healthcare department earn a relatively high salary as well, averaging $115,053 per year. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia, Veklury (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression, Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury (Remdesivir) Due to Presence of Glass Particulates, Gilead Statement on Veklury (Remdesivir) and the SARS-CoV-2 Omicron Variant, Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir, Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy for Pre-Exposure Prophylaxis in the European Union, Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy) in Second-Line and Later Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees, Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States, Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis, Gilead Sciences Response to Open Letter Regarding Access to AmBisome (liposomal amphotericin B), Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Phase 3 Veklury (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19, Gilead Announces Additional Updates to The Advancing ACCESS Patient Assistance/Medication Assistance Program, Gilead Announces Updates to The Advancing ACCESS Patient Assistance/Medication Assistance Program, Gilead Announces Plans for New Location in North Carolinas Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD.

Uss Winston Churchill Commanding Officer, Ensuring Strict Accordance With The Periodic Maintenance Requirements, How To Access Variable Outside Function In Javascript, Obituaries St Cloud Times Obituaries, Articles E